Penicillin-based anti-infectives are among the most important pharmaceutical
products in the world in terms of volume. The products in DSM Anti-Infectives’
current portfolio are very effective in combating a broad spectrum of
bacterial and fungal infections in both humans and animals and as such are of
vital importance for people’s well-being and healthier economics in farming.
Strategy
As a relatively cheap treatment against infectious
diseases, penicillin-derived pharmaceuticals can be afforded by a large and
growing part of mankind, with pronounced growth in the developing economies of
China, India, other countries in Asia and Africa. Consumption in the Western
world with its highly regulated markets is more or less stable. DSM
Anti-Infectives is the only penicillin producer outside of China.
In this context DSM Anti-Infectives – as the leading supplier of bulk active
ingredients and important intermediates – has defined a strategy that is aimed
at actively maintaining this leadership position via customer intimacy in the
different markets and technological innovations leading to both further
improved production (cost effective and leaving less of an environmental
footprint) and a strengthened product portfolio in generic active ingredients.
DSM Anti-Infectives will achieve this by actively seeking partnerships, and
where necessary rationalizing parts of the portfolio.
